Domaine

Découverte et pharma

Cibles, molécules, et relier un dossier à un essai.

2 scénarios

Publié

A generative-AI-designed molecule in a phase 2a IPF trial

Insilico Medicine used a generative platform to propose TNIK as a target in idiopathic pulmonary fibrosis and to design rentosertib (formerly ISM001-055). Nature Medicine published a 12-week randomized phase 2a trial in 2025. The primary endpoint was safety, not lung function. The molecule is investigational. A small secondary signal is not an approved therapy.

Pharma.AI · Insilico Medicine · rentosertib (ISM001-055)

Article · 2025Lire le cas

Découverte et pharma

Matching a cancer chart to trial eligibility

Trial-matching tools read structured fields and sometimes the free-text note to list studies a patient might qualify for. Tempus, Flatiron, and Deep 6 AI are examples of companies that sell a version of this. A research coordinator still checks every criterion against the chart. A match list is not enrollment, and it is not a treatment recommendation.

Tempus · Flatiron · Deep 6 AI

Fournisseur · 2025Lire le cas